|
|
|
|
| LEADER |
00000cam a22000007a 4500 |
| 001 |
on1392163725 |
| 003 |
OCoLC |
| 005 |
20240623213015.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
230805s2023 sz o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d GW5XE
|d EBLCP
|d OCLCQ
|d YDX
|d SFB
|d OCLCO
|d VLB
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1392342471
|a 1403850959
|a 1409048329
|
| 020 |
|
|
|a 9783031384370
|q electronic book
|
| 020 |
|
|
|a 3031384377
|q electronic book
|
| 020 |
|
|
|z 9783031384363
|q hardcover
|
| 020 |
|
|
|z 3031384369
|q hardcover
|
| 024 |
7 |
|
|a 10.1007/978-3-031-38437-0
|2 doi
|
| 035 |
|
|
|a (OCoLC)1392163725
|z (OCoLC)1392342471
|z (OCoLC)1403850959
|z (OCoLC)1409048329
|
| 050 |
|
4 |
|a QP535.C2
|b V65 2023eb
|
| 072 |
|
7 |
|a MMG
|2 bicssc
|
| 072 |
|
7 |
|a MED071000
|2 bisacsh
|
| 072 |
|
7 |
|a MKG
|2 thema
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Voltage-gated CA2+ channels :
|b pharmacology, modulation and their role in human disease /
|c Jörg Striessnig, editor.
|
| 264 |
|
1 |
|a Cham :
|b Springer,
|c 2023.
|
| 264 |
|
4 |
|c ©2023
|
| 300 |
|
|
|a 1 online resource (xii, 155 pages).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Handbook of Experimental Pharmacology ;
|v volume 279
|
| 520 |
|
|
|a The aim of this volume is to summarize novel findings on the function, pathophysiology, and regulation of voltage-gated Ca2+ channels and on novel concepts of their pharmacological modulation. Impressive insights into the role of channel function and regulation have come from Ca2+ channelopathies affecting the pore-forming as well as accessory subunits and channel-interacting proteins. Moreover, the long-sought molecular basis for key regulatory pathways have been discovered as well as exciting concepts of their subtype-selective pharmacological modulation.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed August 11, 2023).
|
| 650 |
|
0 |
|a Calcium channels.
|
| 700 |
1 |
|
|a Striessnig, Jörg.
|
| 776 |
0 |
8 |
|c Original
|z 3031384369
|z 9783031384363
|w (OCoLC)1385450597
|
| 830 |
|
0 |
|a Handbook of experimental pharmacology ;
|v v. 279.
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-031-38437-0
|y Click for online access
|
| 880 |
0 |
|
|6 505-00/(S
|a Part I Modulation -- Ca V1.1 Calcium Channel Signaling Complexes in Excitation-Contraction Coupling: Insights from Channelopathies -- Mechanisms of Vascular CaV 1.2 Channel Regulation During Diabetic Hyperglycemia -- Sympathetic Nervous System Regulation of Cardiac Calcium Channels -- Modulation of Ca V 1.2 Channel Function by Interacting Proteins and Post-Translational Modifications: Implications in Cardiovascular Diseases and COVID-19 -- Part II Pharmacological Approaches -- The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson's Disease -- Design and Applications of Genetically-Encoded Voltage-Dependent Calcium Channel Inhibitors -- Part III Disease Insight from Channelopathies: Consequences for Pharmacology and Therapeutic Strategies --CACNA1C-Related Channelopathies -- CACNA1D-Related Channelopathies: From Hypertension to Autism -- CACNA1A-Related Channelopathies: Clinical Manifestations and Treatment Options -- Ca V3.2 (CACNA1H) in Primary Aldosteronism -- Ca V3.3 Channelopathies -- Pathophysiological Roles of Auxiliary Calcium Channel α2δ Subunits.
|
| 903 |
|
|
|a SPRING-ALL2023
|
| 994 |
|
|
|a 92
|b HCD
|